Literature DB >> 26602765

Controlling Cerebellar Output to Treat Refractory Epilepsy.

Lieke Kros1, Oscar H J Eelkman Rooda1, Chris I De Zeeuw2, Freek E Hoebeek3.   

Abstract

Generalized epilepsy is characterized by recurrent seizures caused by oscillatory neuronal firing throughout thalamocortical networks. Current therapeutic approaches often intervene at the level of the thalamus or cerebral cortex to ameliorate seizures. We review here the therapeutic potential of cerebellar stimulation. The cerebellum forms a prominent ascending input to the thalamus and, whereas stimulation of the foliated cerebellar cortex exerts inconsistent results, stimulation of the centrally located cerebellar nuclei (CN) reliably stops generalized seizures in experimental models. Stimulation of this area indicates that the period of stimulation with respect to the phase of the oscillations in thalamocortical networks can optimize its effect, opening up the possibility of developing on-demand deep brain stimulation (DBS) treatments.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cerebellar nuclei; deep brain stimulation (DBS); refractory epilepsy

Mesh:

Year:  2015        PMID: 26602765     DOI: 10.1016/j.tins.2015.10.002

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  24 in total

1.  Bidirectional Control of Generalized Epilepsy Networks via Rapid Real-Time Switching of Firing Mode.

Authors:  Jordan M Sorokin; Thomas J Davidson; Eric Frechette; Armen M Abramian; Karl Deisseroth; John R Huguenard; Jeanne T Paz
Journal:  Neuron       Date:  2016-12-15       Impact factor: 17.173

2.  Excitation, but not inhibition, of the fastigial nucleus provides powerful control over temporal lobe seizures.

Authors:  Martha L Streng; Esther Krook-Magnuson
Journal:  J Physiol       Date:  2019-12-09       Impact factor: 5.182

Review 3.  Recent advances in epilepsy.

Authors:  Mark Manford
Journal:  J Neurol       Date:  2017-01-24       Impact factor: 4.849

Review 4.  Therapeutic Basis of Generic Substitution of Antiseizure Medications.

Authors:  Sarah Elmer; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2022-03-03       Impact factor: 4.402

5.  Deep Relational Reasoning for the Prediction of Language Impairment and Postoperative Seizure Outcome Using Preoperative DWI Connectome Data of Children With Focal Epilepsy.

Authors:  Soumyanil Banerjee; Ming Dong; Min-Hee Lee; Nolan O'Hara; Csaba Juhasz; Eishi Asano; Jeong-Won Jeong
Journal:  IEEE Trans Med Imaging       Date:  2021-03-02       Impact factor: 10.048

6.  Disrupted functional connectivity in white matter resting-state networks in unilateral temporal lobe epilepsy.

Authors:  Xuan Li; Yuchao Jiang; Wei Li; Yingjie Qin; Zhiliang Li; Yan Chen; Xin Tong; Fenglai Xiao; Xiaojun Zuo; Qiyong Gong; Dong Zhou; Dezhong Yao; Dongmei An; Cheng Luo
Journal:  Brain Imaging Behav       Date:  2021-09-03       Impact factor: 3.978

7.  Deep Brain Stimulation in Epilepsy: A Role for Modulation of the Mammillothalamic Tract in Seizure Control?

Authors:  Frédéric L W V J Schaper; Birgit R Plantinga; Albert J Colon; G Louis Wagner; Paul Boon; Nadia Blom; Erik D Gommer; Govert Hoogland; Linda Ackermans; Rob P W Rouhl; Yasin Temel
Journal:  Neurosurgery       Date:  2020-09-01       Impact factor: 4.654

Review 8.  The cerebellum and epilepsy.

Authors:  Martha L Streng; Esther Krook-Magnuson
Journal:  Epilepsy Behav       Date:  2020-02-05       Impact factor: 3.337

9.  Distinct effects of the basal ganglia and cerebellum on the thalamocortical pathway in idiopathic generalized epilepsy.

Authors:  Jinnan Gong; Sisi Jiang; Zhiliang Li; Haonan Pei; Qifu Li; Dezhong Yao; Cheng Luo
Journal:  Hum Brain Mapp       Date:  2021-04-08       Impact factor: 5.038

10.  Cerebellar Dysfunction and Ataxia in Patients with Epilepsy: Coincidence, Consequence, or Cause?

Authors:  Václav Marcián; Pavel Filip; Martin Bareš; Milan Brázdil
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2016-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.